期刊
BIOCHEMICAL JOURNAL
卷 443, 期 -, 页码 735-746出版社
PORTLAND PRESS LTD
DOI: 10.1042/BJ20111685
关键词
apoptosis; CS055; differentiation; histone deacetylase inhibitor (HDACi); leukaemia; proliferation inhibition; reactive oxygen species (ROS)
资金
- National Basic Research Program of China [201008529800]
- National Nature Science Foundation of China [30871261, 81072151]
- Chinese 111 project [B06018]
- Fundamental Research Funds for the Central Universities [3081009]
- Nature Science Foundation of Hubei Province [2008CDB080]
- Program for Chenguang Young Scientist for Wuhan [200950431188]
- Scientific Research Foundation for Returned Overseas Scholars, State Education Ministry
CS055 (Chidamide/HBI-8000) is a novel benzamide-type HDACi (histone deacetylase inhibitor), which has entered Phase I clinical trials in the U.S. and Phase II/III in China. In the present study, we investigated the effects of CS055 on proliferation, differentiation and apoptosis in human leukaemia cell lines and primary myeloid leukaemia cells. The results showed that at low concentrations (<1 mu M), CS055 induced G(1) arrest. At moderate concentrations (0.5 mu M-2 mu M), CS055 induced differentiation, as determined by the increased expression of the myeloid differentiation marker CD11b. At relatively high concentrations (2 mu M-4 mu M), CS055 potently induced caspase-dependent apoptosis. Co-treatment with the ROS (reactive oxygen species) scavengers N-acetyl-L-cysteine or Tiron blocked CS055-induced cell differentiation and apoptosis, suggesting an essential role for ROS in these effects. Cytochrome c release and ROS-mediated mitochondrial dysfunction are involved in CS055-induced apoptosis of leukaemia. In addition to cell lines, CS055 also exhibits therapeutic effects in human primary leukaemia cells. Moreover, daily oral CS055 treatment of nude mice bearing HL60 cell xenografts suppressed tumour growth, induced tumour cell apoptosis and prolonged the survival of tumour-bearing mice. In conclusion, our findings demonstrate that CS055 is a novel HDACi with potential chemotherapeutic value in several haematological malignancies, especially leukaemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据